Zobrazeno 1 - 10
of 9 141
pro vyhledávání: '"virological response"'
Autor:
P. O. Bogomolov, N. A. Shub, N. A. Gasilova, A. A. Belyakova, T. G. Lidzhieva, E. A. Kondrasheva, N. A. Barsukova, M. V. Arapova, E. A. Isaeva, S. V. Koblov, M. V. Kalashnikov, O. S. Kuzymina, A. Yu. Demyanov, A. O. Bueverov, I. V. Maev
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 34, Iss 5, Pp 40-46 (2024)
Aim: to evaluate the significance of a positive polymerase chain reaction result for hepatitis D virus RNA (HDV RNA) in liver biopsy specimens of patients with chronic hepatitis D (CHD) after completion of antiviral therapy (AVT) as a predictor of in
Externí odkaz:
https://doaj.org/article/93bd69b322bc469fbdc26ae6022e8f8c
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 2115-2132 (2024)
Mohsen Salama,* Nehad Darwesh,* Maha Mohammad Elsabaawy,* Eman Abdelsameea,* Asmaa Gomaa,* Aliaa Sabry* Department of Hepatology and Gastroenterology, National Liver Institute, Menofia University, Shebeen El-Kom, Menofia, Egyp
Externí odkaz:
https://doaj.org/article/d122c8dab3474b9c818f4181a639cbca
Autor:
Yuko Nagaoki, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Hiroshi Aikata, C. Nelson Hayes, Masataka Tsuge, Shiro Oka
Publikováno v:
Livers, Vol 4, Iss 3, Pp 352-363 (2024)
To clarify the risk factors for the aggravation of esophagogastric varices (EGVs) after hepatitis C virus (HCV) eradication with direct-acting antiviral (DAA) therapy, we enrolled 167 consecutive patients with HCV-related compensated cirrhosis who ac
Externí odkaz:
https://doaj.org/article/9561c7e746144a2781c2f6ff47ab51b5
Autor:
Genoveva Cuesta, Judit Cacho, David Cucchiari, Sabina Herrera, Abiu Sempere, Tabassum Akter, Anna Villasante, Miriam Garrido, Frederic Cofan, Fritz Diekmann, Alex Soriano, Maria Angeles Marcos, Marta Bodro
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 7, Pp 1703-1713 (2024)
Abstract Introduction There is no reliable microbiological marker to guide responses to antiviral treatment in kidney transplant recipients (KTR) with COVID-19. We aimed to evaluate the dynamics of subgenomic RNA (sgRNA) RT-PCR before and after recei
Externí odkaz:
https://doaj.org/article/11d48094aeae4ce5ba9e59d121fd767b
Autor:
Takeshi Chida, Kazuyoshi Ohta, Hidenao Noritake, Masahiro Matsushita, Gou Murohisa, Fujito Kageyama, Yuzo Sasada, Tatsuki Oyaizu, Minoru Tsugiki, Katsutoshi Tamakoshi, Takeyuki Nakajima, Takafumi Suda, Kazuhito Kawata
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Lysyl oxidase-like 2 (LOXL2) mediates the crosslinking of extracellular collagen, reflecting qualitative changes in liver fibrosis. This study aimed to validate the utility of serum LOXL2 levels as a predictive biomarker for the development
Externí odkaz:
https://doaj.org/article/2bce7fd31c9a4d30a37a2d1e98ff83b9
Autor:
Zhong-Bin Li, Dan-Dan Chen, Yun-Fei Jia, Qing-Juan He, Li Cui, Feng-Xia Du, Yao-Jie Kang, Xin Feng, Mengwen He, Xue-Yuan Jin, Jing Chen, Yudong Wang, Dong Ji, George Lau, Shu-Gao Wu
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 14 (2024)
BackgroundAbout 20% of on-treatment patients with chronic hepatitis B (CHB) experienced low-level viraemia (LLV), which is associated with persistent low-grade inflammation, fibrosis progression, and increased risk of hepatocellular carcinoma. We aim
Externí odkaz:
https://doaj.org/article/b040c0ad7cca4e1a80aaec9a3c154cda
Publikováno v:
Infectious Agents and Cancer, Vol 19, Iss 1, Pp 1-12 (2024)
Abstract Background Hepatitis C patients with advanced fibrosis or cirrhosis are at high risk of developing hepatocellular carcinoma (HCC), even after sustained virological response (SVR). Clinical recommendations impose a significant burden on patie
Externí odkaz:
https://doaj.org/article/9ba8e0fda4ae4aad9c5c033e74af2581
Autor:
Yunjing Zhou, Minfeng Liang, Yiting Li, Xing Chen, Jie Yang, Honglian Bai, Yingzi Long, Xiaohong Zhang, Chaoshuang Lin
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background Sofosbuvir/Velpatasvir (Epclusa, ECS) is the first pan-genotype direct-acting antiviral agent (DAA) for hepatitis C virus (HCV) infection, and Danoprevir (DNV) is the first DAA developed by a Chinese local enterprise, which is sui
Externí odkaz:
https://doaj.org/article/dd38705deae74d5c9785e10b82c07fd7
Autor:
Chun-Yuan Lee, Yi-Pei Lin, Chun-Yu Lin, Tun-Chieh Chen, Shin-Huei Kuo, Shih-Hao Lo, Sheng-Fan Wang, Po-Liang Lu
Publikováno v:
Journal of Infection and Public Health, Vol 17, Iss 2, Pp 339-348 (2024)
Background: Late cART initiation (CD4 count ≤200 cells/μL or AIDS-defining opportunistic illnesses [AOIs] at cART initiation) impedes CD4 count recovery and virologic suppression after cART initiation. However, studies to evaluate trends of and mo
Externí odkaz:
https://doaj.org/article/e56757cbe7944e3aba4f23bc0e3afdd7
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background To investigate the trends in health-related quality of life (HRQoL) among hepatitis C virus (HCV) patients and to assess the longitudinal impact of antiviral therapy on their well-being. Methods In this prospective multicenter obs
Externí odkaz:
https://doaj.org/article/ac6451c3d0c1414aa141f16899c06b1f